Publicacións nas que colabora con Joaquín Casal Rubio (12)
2022
2021
-
Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group
Journal of Geriatric Oncology, Vol. 12, Núm. 3, pp. 410-415
2020
-
PD-(L)1 inhibitors in combination with chemotherapy as first-line treatment for non-small-cell lung cancer: A pairwise meta-analysis
Journal of Clinical Medicine, Vol. 9, Núm. 7, pp. 1-13
2015
-
Erlotinib as second-line therapy for patients with advanced non-small-cell lung cancer and wild-type EGFR tumors
Journal of Analytical Oncology, Vol. 4, Núm. 3, pp. 94-101
2014
-
A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): A Galician Lung Cancer Group (GGCP) study
Cancer Chemotherapy and Pharmacology, Vol. 73, Núm. 3, pp. 451-457
-
Full-dose cisplatin and oral vinorelbine concomitant with radiotherapy in unresectable stage III non-small cell lung cancer: A multi-center phase II study
Anticancer Research, Vol. 34, Núm. 4, pp. 1959-1966
-
Second-line treatment in advanced non-small-cell lung cancer in the epidermal growth factor receptor wild-type population: Review of patient profile
Anti-Cancer Drugs, Vol. 25, Núm. 4, pp. 368-374
2012
-
First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients
Expert Opinion on Pharmacotherapy, Vol. 13, Núm. 10, pp. 1389-1396
2009
-
A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma
Cancer Chemotherapy and Pharmacology, Vol. 64, Núm. 2, pp. 379-384
2007
-
Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: A phase II study of the Galician Lung Cancer Group (GGCP 013-02)
Anti-Cancer Drugs, Vol. 18, Núm. 10, pp. 1201-1206
-
Guía de práctica clínica: cancro de pulmón e mesotelioma
Conselleria de Sanidade